title: Caspase inhibitors for the treatment of liver disease: friend or foe?
authors.affiliation: a Department of Pharmacology, Toxicology and Therapeutics , University of Kansas Medical Center , Kansas City , KS , USA.
authors.forename: Benjamin L
authors.initials: BL
authors.lastname: Woolbright
authors.affiliation: a Department of Pharmacology, Toxicology and Therapeutics , University of Kansas Medical Center , Kansas City , KS , USA.
authors.forename: Wen-Xing
authors.initials: WX
authors.lastname: Ding
authors.affiliation: a Department of Pharmacology, Toxicology and Therapeutics , University of Kansas Medical Center , Kansas City , KS , USA.
authors.forename: Hartmut
authors.initials: H
authors.lastname: Jaeschke
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D051017:Apoptosis Regulatory Proteins / Q000378:metabolism; D061945:Caspase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D008107:Liver Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D012307:Risk Factors; D015398:Signal Transduction / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D051017:Apoptosis Regulatory Proteins; D061945:Caspase Inhibitors
keywords: Apoptosis; TNF-alpha; acetaminophen; caspase inhibitors; cholestasis; galactosamine-endotoxin; hepatotoxicity; ischemia-reperfusion; necroptosis